Abstract | INTRODUCTION: METHODS: Data were based on three double-blind, placebo-controlled, phase 3 studies. Patients (1773 episodic and 1113 chronic) were randomized (2:1:1) to monthly doses of placebo, galcanezumab 120 mg with a 240 mg loading dose, or galcanezumab 240 mg (January 2016-March 2017). Onset of effect was determined using a sequential analysis approach based on earliest time point at which galcanezumab achieved and subsequently maintained statistical superiority to placebo. Maintenance of effect was a comparison of the percentages of galcanezumab- and placebo-treated patients with maintenance of at least 50% response at the individual patient level. Cessation of effect was determined during a 4-month post-treatment period on the basis of change from baseline in monthly migraine headache days. RESULTS:
Galcanezumab led to a lower percentage of patients who had a migraine headache on the first day after injection, provided maintenance of effect throughout the duration of the double-blind treatment period, and gradually lost effect without signs of rebound headache throughout the post-treatment period in most patients with episodic and chronic migraine. CONCLUSION:
Galcanezumab is a novel preventive therapeutic option for adult patients with migraine that has early onset of action, maintenance of effect, and gradual reduction of effect upon treatment cessation. TRIAL REGISTRATION: ClinicalTrials.gov: NCT02614183 (EVOLVE-1); NCT02614196 (EVOLVE-2); NCT02614261 (REGAIN).
|
Authors | Dulanji K Kuruppu, James M North, Amy J Kovacik, Yan Dong, Eric M Pearlman, Susan L Hutchinson |
Journal | Advances in therapy
(Adv Ther)
Vol. 38
Issue 3
Pg. 1614-1626
(03 2021)
ISSN: 1865-8652 [Electronic] United States |
PMID | 33544305
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Antibodies, Monoclonal, Humanized
- galcanezumab
- Calcitonin Gene-Related Peptide
|
Topics |
- Adult
- Antibodies, Monoclonal, Humanized
- Calcitonin Gene-Related Peptide
- Double-Blind Method
- Humans
- Migraine Disorders
(drug therapy, prevention & control)
- Randomized Controlled Trials as Topic
- Treatment Outcome
|